Study on the indication of concurrent chemoradiotherapy for locally advanced laryngeal carcinoma
-
摘要: 喉癌是头颈部常见的恶性肿瘤之一，美国国立综合癌症网络(NCCN)临床实践指南认为同步放化疗是局部晚期喉癌最有效的器官保护策略，可在不降低患者生存率的前提下保留患者喉部。非T4(T1~3)、高淋巴结负担(N2~3)的喉癌患者可以从同步放化疗中受益，相较于其他分期的局部晚期喉癌更适合接受同步放化疗。本文就同步放化疗的适应证进行探讨。Abstract: Laryngeal cancer is one of the most common malignant cancer of the head and neck. Concurrent chemoradiotherapy is considered by the NCCN guideline to be the most effective organ protection strategy for locally advanced laryngeal cancer, which can preserve the larynx without reducing the survival rate of patients. Patients with non-T4 (T1-3) and high lymph node burden (N2-3) laryngeal cancer can benefit from concurrent chemoradiotherapy, which are more suitable for concurrent chemoradiotherapy than locally advanced laryngeal cancer with other stages. The indications of concurrent chemoradiotherapy were further discussed in this paper.
-
Key words:
- laryngeal neoplasms /
- radiotherapy /
- chemotherapy /
- indications
-
-
[1] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019[J]. CA Cancer J Clin, 2019, 69(1): 7-34. doi: 10.3322/caac.21551
[2] Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. doi: 10.3322/caac.21660
[3] 乐慧君, 陈思宇, 李芸, 等. 喉癌诊疗策略及进展[J]. 临床耳鼻咽喉头颈外科杂志, 2019, 33(11): 1017-1021. https://www.cnki.com.cn/Article/CJFDTOTAL-LCEH201911003.htm
[4] Gallaway MS, Henley SJ, Steele CB, et al. Surveillance for Cancers Associated with Tobacco Use-United States, 2010-2014[J]. MMWR Surveill Summ, 2018, 67(12): 1-42. doi: 10.15585/mmwr.ss6712a1
[5] Nehlsen AD, Lehrer EJ, Dickstein DR, et al. Functional Larynx Preservation in Patients With Locally Advanced Squamous Cell Carcinoma of the Larynx and Hypopharynx Treated With Induction Chemotherapy vs. Concurrent Chemoradiation Alone[J]. Cureus, 2021, 13(7): e16310.
[6] Pfister DG, Spencer S, Adelstein D, et al. Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology[J]. J Natl Compr Canc Netw, 2020, 18(7): 873-898. doi: 10.6004/jnccn.2020.0031
[7] Wushouer A, Li W, Zhang M, et al. Comparison of treatment modalities for selected advanced laryngeal squamous cell carcinoma[J]. Eur Arch Otorhinolaryngol, 2022, 279(1): 361-371. doi: 10.1007/s00405-021-06780-y
[8] Marchi F, Filauro M, Missale F, et al. A Multidisciplinary Team Guided Approach to the Management of cT3 Laryngeal Cancer: A Retrospective Analysis of 104 Cases[J]. Cancers(Basel), 2019, 11(5): 717.
[9] Nishimura Y. Rationale for chemoradiotherapy[J]. Int J Clin Oncol, 2004, 9(6): 414-420. doi: 10.1007/s10147-004-0443-z
[10] Okumura M, Motegi A, Zenda S, et al. Efficacy and safety of accelerated fractionated radiotherapy without elective nodal irradiation for T3N0 glottic cancer without vocal cord fixation[J]. Head Neck, 2020, 42(8): 1775-1782. doi: 10.1002/hed.26092
[11] Caudell JJ, Gillison ML, Maghami E, et al. NCCN Guidelines® Insights: Head and Neck Cancers, Version 1.2022[J]. J Natl Compr Canc Netw, 2022, 20(3): 224-234. doi: 10.6004/jnccn.2022.0016
[12] Jung EK, Jin SM, Kim JG, et al. Comparison of long-term treatment outcomes of T2N0M0 laryngeal squamous cell carcinoma using different treatment methods[J]. Oncol Lett, 2020, 20(1): 921-930. doi: 10.3892/ol.2020.11628
[13] Heineman TE, Kuan EC, St John MA. When should surveillance imaging be performed after treatment for head and neck cancer?[J]. Laryngoscope, 2017, 127(3): 533-534. doi: 10.1002/lary.26268
[14] Ho AS, Tsao GJ, Chen FW, et al. Impact of positron emission tomography/computed tomography surveillance at 12 and 24 months for detecting head and neck cancer recurrence[J]. Cancer, 2013, 119(7): 1349-1356. doi: 10.1002/cncr.27892
[15] Jain TK, Singh G, Goyal S, et al. Should fluorodeoxyglucose positron emission tomography/computed tomography be the first-line imaging investigation for restaging the laryngeal carcinoma patients?[J]. World J Nucl Med, 2021, 20(2): 164-171. doi: 10.4103/wjnm.WJNM_95_20
[16] Wu Y, Zhang L, Tang T, et al. Postoperative Radiotherapy Omitting Level Ⅳ for Locally Advanced Supraglottic and Glottic Laryngeal Carcinoma[J]. Technol Cancer Res Treat, 2021, 20: 1533033820985876.
[17] Rodrigo JP, García-Velasco F, Ambrosch P, et al. Transoral laser microsurgery for glottic cancer in the elderly: Efficacy and safety[J]. Head Neck, 2019, 41(6): 1816-1823. doi: 10.1002/hed.25616
[18] Chien PJ, Hung LT, Wang LW, et al. Oncologic results and quality of life in patients with T3 glottic cancer after transoral laser microsurgery[J]. Eur Arch Otorhinolaryngol, 2021, 278(8): 2983-2992. doi: 10.1007/s00405-020-06445-2
[19] Patel SA, Qureshi MM, Dyer MA, et al. Comparing surgical and nonsurgical larynx-preserving treatments with total laryngectomy for locally advanced laryngeal cancer[J]. Cancer, 2019, 125(19): 3367-3377. doi: 10.1002/cncr.32292
[20] Nakai MY, Menezes MB, de Carvalho J, et al. Quality of life after Supracricoid Partial Laryngectomy[J]. J Otolaryngol Head Neck Surg, 2021, 50(1): 20. doi: 10.1186/s40463-021-00499-w
[21] Department of Veterans Affairs Laryngeal Cancer Study Group, Wolf GT, Fisher SG, et al. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer[J]. N Engl J Med, 1991, 324(24): 1685-1690. doi: 10.1056/NEJM199106133242402
[22] Forastiere AA, Zhang Q, Weber RS, et al. Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer[J]. J Clin Oncol, 2013, 31(7): 845-852. doi: 10.1200/JCO.2012.43.6097
[23] Dagan O, Moore A, Nachalon Y, et al. Induction chemotherapy for locally advanced laryngeal and hypopharyngeal cancer: Single institution experience[J]. Head Neck, 2020, 42(11): 3118-3124. doi: 10.1002/hed.26353
[24] Janoray G, Pointreau Y, Alfonsi M, et al. Induction chemotherapy followed by cisplatin or cetuximab concomitant to radiotherapy for laryngeal/hypopharyngeal cancer: Long-term results of the TREMPLIN randomised GORTEC trial[J]. Eur J Cancer, 2020, 133: 86-93. doi: 10.1016/j.ejca.2020.04.009
[25] Al-Saleh K, El-Sherify M, Safwat R, et al. Phase Ⅱ/Ⅲ Randomized Controlled Trial of Concomitant Hyperfractionated Radiotherapy plus Cetuximab(Anti-EGFR Antibody)or Chemotherapy in Locally Advanced Head and Neck Cancer[J]. Gulf J Oncolog, 2019, 1(30): 6-12.
[26] Pontes F, Garcia AR, Domingues I, et al. Survival predictors and outcomes of patients with recurrent and/or metastatic head and neck cancer treated with chemotherapy plus cetuximab as first-line therapy: A real-world retrospective study[J]. Cancer Treat Res Commun, 2021, 27: 100375. doi: 10.1016/j.ctarc.2021.100375
[27] Lee NY, Ferris RL, Psyrri A, et al. Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial[J]. Lancet Oncol, 2021, 22(4): 450-462. doi: 10.1016/S1470-2045(20)30737-3
[28] Sinha S, Agarwal JP, Mahajan A, et al. Implications of limited exolaryngeal disease and cricoarytenoid joint involvement in organ conservation protocols for laryngopharyngeal cancers: Results from a prospective study[J]. Head Neck, 2021, 43(4): 1289-1299. doi: 10.1002/hed.26593
[29] 王凯, 曲媛, 易俊林, 等. 局部晚期头颈部鳞癌不同治疗方法的Ⅲ期随机对照研究再分析[J]. 中华放射肿瘤学杂志, 2020, 29(7): 502-507. doi: 10.3760/cma.j.cn113030-20200412-00179
[30] Gouw Z, La Fontaine MD, Vogel WV, et al. Single-Center Prospective Trial Investigating the Feasibility of Serial FDG-PET Guided Adaptive Radiation Therapy for Head and Neck Cancer[J]. Int J Radiat Oncol Biol Phys, 2020, 108(4): 960-968. doi: 10.1016/j.ijrobp.2020.04.030
[31] Ward MC, Adelstein DJ, Bhateja P, et al. Severe late dysphagia and cause of death after concurrent chemoradiation for larynx cancer in patients eligible for RTOG 91-11[J]. Oral Oncol, 2016, 57: 21-26. doi: 10.1016/j.oraloncology.2016.03.014
[32] Arain AA, Rajput M, Akhtar S, et al. Organ Preservation for Advanced Laryngeal Cancer: Experience with Concurrent Chemoradiation Therapy[J]. Cureus, 2020, 12(4): e7553.
[33] Dietz A, Wiegand S, Kuhnt T, et al. Laryngeal Preservation Approaches: Considerations for New Selection Criteria Based on the DeLOS-Ⅱ Trial[J]. Front Oncol, 2019, 9: 625. doi: 10.3389/fonc.2019.00625
-
计量
- 文章访问数: 1244
- PDF下载数: 561
- 施引文献: 0
下载: